Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S P Joel

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Cancer Chemotherapy and Pharmacology|January 1, 1994
Schedule-dependent topoisomerase II-inhibiting drugsS P Joel, M L Slevin
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 1, 1993
Prolonged oral etoposide in small cell lung cancerM L Slevin, S P Joel
British Journal of Cancer|December 22, 1999
Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell linesR H te Poele, S P Joel
Cancer Chemotherapy and Pharmacology|January 1, 1994
Etoposide dosage and pharmacodynamicsS P Joel, R Shah, M L Slevin
Journal of Chromatography|September 9, 1988
An improved method for the simultaneous determination of morphine and its principal glucuronide metabolitesS P Joel, R J Osborne, M L Slevin
Cancer Chemotherapy and Pharmacology|January 1, 1995
Stability of the i.v. and oral formulations of etoposide in solutionS P Joel, P I Clark, M L Slevin
British Journal of Cancer|May 3, 2002
The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agentsW M Liu, L A Stimson, S P Joel
European Journal of Cancer (Oxford, England : 1990)|April 9, 2002
The importance of drug scheduling and recovery phases in determining drug activity. Improving etoposide efficacy in BCR-ABL-positive CML cellsW M Liu, A J Lawrence, S P Joel
Journal of Pharmaceutical and Biomedical Analysis|March 1, 1994
Evaluation of a differential radioimmunoassay technique for the determination of morphine and morphine-6-glucuronide in human plasmaD J Chapman, S P Joel, G W Aherne
Leukemia|August 30, 2002
Exposure to low concentrations of etoposide reduces the apoptotic capability of leukaemic cell linesW M Liu, P R Oakley, S P Joel
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Cancer Chemotherapy and Pharmacology|January 1, 1994
Schedule-dependent topoisomerase II-inhibiting drugsS P Joel, M L Slevin
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 1, 1993
Prolonged oral etoposide in small cell lung cancerM L Slevin, S P Joel
British Journal of Cancer|December 22, 1999
Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell linesR H te Poele, S P Joel
Cancer Chemotherapy and Pharmacology|January 1, 1994
Etoposide dosage and pharmacodynamicsS P Joel, R Shah, M L Slevin
Journal of Chromatography|September 9, 1988
An improved method for the simultaneous determination of morphine and its principal glucuronide metabolitesS P Joel, R J Osborne, M L Slevin
Cancer Chemotherapy and Pharmacology|January 1, 1995
Stability of the i.v. and oral formulations of etoposide in solutionS P Joel, P I Clark, M L Slevin
British Journal of Cancer|May 3, 2002
The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agentsW M Liu, L A Stimson, S P Joel
European Journal of Cancer (Oxford, England : 1990)|April 9, 2002
The importance of drug scheduling and recovery phases in determining drug activity. Improving etoposide efficacy in BCR-ABL-positive CML cellsW M Liu, A J Lawrence, S P Joel
Journal of Pharmaceutical and Biomedical Analysis|March 1, 1994
Evaluation of a differential radioimmunoassay technique for the determination of morphine and morphine-6-glucuronide in human plasmaD J Chapman, S P Joel, G W Aherne
Leukemia|August 30, 2002
Exposure to low concentrations of etoposide reduces the apoptotic capability of leukaemic cell linesW M Liu, P R Oakley, S P Joel
Pageof 5